The shift towards biotech-derived products represents a significant therapeutic shift, according to Evaluate Pharma. Evaluate also forecasts that over 50 percent of the top 100 drugs in 2014 will be biotech medications, which marks a significant shift from 28 percent in 2008 and 11 percent in 2000. It explains why Big Pharma has been pursuing biotech relentlessly.
Those stepping into a career in Biologics have reason to smile while marketing grads need to put their thinking caps on and get a little perspective.